Risk factors, molecular analysis and treatment outcomes of amikacin-resistant <i>Mycobacterium avium</i> complex pulmonary disease
Better management strategies for patients with severe and refractory MAC-PD are crucial. This includes placing a strong emphasis on preventing AMK resistance.
Authors
- Keisuke Kamada (ORCID: https://orcid.org/0000-0001-7034-4376)
- Kinuyo Chikamatsu
- Kozo Morimoto (ORCID: https://orcid.org/0000-0002-8239-9275)
- Satoshi Mitarai (ORCID: https://orcid.org/0000-0002-2288-077X)
- Koji Furuuchi (ORCID: https://orcid.org/0000-0002-1208-7698)
- Takashi Yoshiyama (ORCID: https://orcid.org/0000-0002-7278-8816)
- Hideo Ogata
- Masashi Ito (ORCID: https://orcid.org/0000-0002-9498-6995)
- Akio Aono (ORCID: https://orcid.org/0000-0003-3478-6892)
- Keiji Fujiwara (ORCID: https://orcid.org/0000-0002-1139-1604)
- Ken Ohta (ORCID: https://orcid.org/0000-0001-9734-4579)
- Fumiya Watanabe (ORCID: https://orcid.org/0000-0001-5272-2249)
- Yoshiro Murase (ORCID: https://orcid.org/0000-0003-0240-8352)
- Tatsuya Kodama (ORCID: https://orcid.org/0000-0002-3877-3397)
- Yuriko Igarashi (ORCID: https://orcid.org/0000-0002-3695-7926)
- Yuji Shiraishi
Institutions
- University of Nagasaki (JP)
- Meiji Pharmaceutical University (JP)
- Japan Anti Tuberculosis Association (JP)
- Fukujuji Hospital (JP)
- Nagasaki University (JP)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1183/23120541.01084-2024
- Citations
- 2
- Primary Topic
- Mycobacterium research and diagnosis
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Japan Agency for Medical Research and Development